光动力疗法抑制人免疫缺陷病毒复制的实验研究

阴慧娟; 郑永唐; 李迎新; 李春艳; 邹朝辉; 赵宇

doi:doi:10.3788/cjl20093610.2705

中国激光, 2009, 36 (10): 2705, 网络出版: 2009-10-23

光动力疗法抑制人免疫缺陷病毒复制的实验研究

Photochemical Inactivation of Cell-Associated and Cell-Free Human Immunodeficiency Virus in Vitro

论文大纲

阴慧娟 ^1,*郑永唐 ²李迎新 ¹李春艳 ²邹朝辉 ¹赵宇 ¹

作者单位

¹ 天津医科大学生物医学工程系激光医学实验室,天津 300070

² 中国科学院昆明动物研究所动物模型与人类疾病机理重点实验室,分子免疫药理学实验室,云南昆明 650223

摘要

通过对人免疫缺陷病毒复制过程的抑制作用研究,探索光动力疗法(PDT)在艾滋病防治中的潜在价值。使用不同稀释浓度的光敏剂血卟啉单甲醚(HMME)和亚甲蓝(MB)分别与人免疫缺陷病毒HIV-1ⅢB或宿主细胞MT4,C8166或H9/HIV-1ⅢB孵育2 h,以波长630 nm能量密度0.3 J/cm2的半导体激光进行照射。继续孵育若干小时后,用噻唑蓝(MTT)比色法检测细胞存活率或合胞体计数,同时收集培养上清液用ELISA法检测HIV-1 p24抗原。结果表明,光动力疗法能显著抑制人免疫缺陷病毒诱导的细胞细胞融合(HMME-PDT抑制率64.68%,MB-PDT抑制率61.56%)和病毒细胞融合(HMME-PDT抑制率85%,MB-PDT抑制率73.64%),并对游离病毒有很强的杀伤作用,最高可达到100%。光动力疗法不能抑制慢性感染期和急性感染2 h后病毒的复制过程。可见光动力疗法对游离病毒和病毒感染诱导的膜融合有显著抑制作用,有可能为艾滋病的防治提供一种新的方法。

Abstract

Aim to explore a potential treatment of AIDS-photodynamic therapy by detecting the photoinaction on hunman immunodeficiency virus (HIV) in vitro,mixed the photosensitizes hematoporphyrin monomethyl ether or methylene blue by a series of dilute strengths with the host cells MT4,C8166 or H9/HIV-1ⅢB or the virus HIV-1ⅢB for 2 hours incubation,followed by irradiation by a 630 nm semiconductor laser with energy density 0.3 J/cm2. After certain time,the activites against HIV-1ⅢB were assayed by determining the syncytial formation under the inverted microscope or MTT and measuring the p24 antigen expression level in supernatant by ELISA. Results show PDT inhibited the cell-cell fusion (inhibition rate,HMME-PDT64.68%,MB-PDT61.56%)and virus-cell fusion (inhibition rate,HMME-PDT 85%,MB-PDT 73.64% )induced by HIV-1ⅢB significantly,and had an intensive inactivation on the cell-free HIV-1ⅢB especially the inhibition rate up to 100%. However,PDT had no effect on the replication course 2 hours after cute infection or chronic infection of HIV-1ⅢB. Therefor PDT has outstanding inhibition on cell-free HIV-1ⅢB and fusion induced by HIV-1ⅢB,which prompts PDT may be a new treatment of AIDS in future.

参考文献

[1] P. G. Calzavara-Pinton,M. Venturini,R. Sala. Photodynamic therapy:update 2006. part 1:Photochemistry and photobiology [J]. J. Eur. Acad. Dermatol. Venereol.,2007,21(3):293-302

[2] A. Juarranz,P. Jaén,F. Sanz-Rodríguez et al.. Photodynamic therapy of cancer. Basic principles and applications [J]. Clin. Transl. Oncol.,2008,10(3):148-154

[3] B. T. Petersen,R. Chuttani,J. Croffie et al.. Photodynamic therapy for gastrointestinal disease [J]. Gastrointest Endosc.,2006,63(7):927-932

[4] A. Sieroń,A. Kociarz-Grzesiok,A. Kawczyk-Krupka et al.. Application of photodynamic therapy in the treatment of premalignant and malignant changes of head and neck[J]. Wiad Lek.,2008,61(10-12):283-287

[5] P. Jichlinski. Photodynamic applications in superficial bladder cancer:facts and hopes [J]. J. Environ. Pathol. Toxicol. Oncol.,2006,25(1-2):441-451

[6] C. M. Moore,D. Pendse,M. Emberton et al.. Photodynamic therapy for prostate cancer a review of current status and future promise[J]. Nat. Clin. Pract. Urol.,2009,6(1):18-30

[7] 张红雨,马文江,邹朝晖等. 光动力法制备抗小鼠H22肝癌的肿瘤疫苗[J]. 中国激光,2008,35(4):631-634

Zhang Hongyu,Ma Wenjiang,Zou Zhaohui et al.. Generation of antitumor vaccines for H22 tumor on mouse using photodynamic therapy[J]. Chinese J. Lasers,2008,35(4):631-634

[8] L. R. Braathen,R. M. Szeimies,N. Basset-Seguin et al.. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer:an international consensus. international society for photodynamic therapy in dermatology,2005[J]. J. Am. Acad. Dermatol.,2007,56(1):125-143

[9] G. Buggiani,M. Troiano,R. Rossi et al.. Photodynamic therapy:off-label and alternative use in dermatological practice [J]. Photodiagn. Photodyn. Ther.,2008,5(2):134-138

[10] J. N. Silva,P. Filipe,P. Morlière et al.. Photodynamic therapy:dermatology and ophthalmology as main fields of current applications in clinic [J]. Biomed. Mater. Eng.,2008,18(4-5):319-327

[11] A. Derkacz. Laser therapy application in invasive cardiology. current state and future trends [J]. Przegl. Lek.,2004,61(1):35-38

[12] M. Wainwright. Local treatment of viral disease using photodynamic therapy [J]. Int. J. Antimicrob. Agents.,2003,21(6):510-520

[13] D. Kacerovska,K. Pizinger,M. Kumpova et al.. Genital warts treated by photodynamic therapy[J]. Skinmed.,2007,6(6):295-297

[14] 薄报学,高欣,乔忠良等. 大功率体光栅外腔半导体激光器的输出特性[J]. 中国激光,2008,35(4):501-504

Bo Baoxue,Gao Xin,Qiao Zhongliang et al.. Characteristics of high power volume-Bragg-grating external cavity semiconductor lasers[J]. Chinese J. Lasers,2008,35(4):501-504

[15] 石家纬,梁庆成,曹军胜等. 高功率半导体激光器电压饱和特性与器件质量[J]. 中国激光,2008,35(9):1346-1349

Shi Jiawei,Liang Qingcheng,Cao Junsheng et al.. Junction voltage saturation and quality of high power semiconductor lasers[J]. Chinese J. Lasers,2008,35(9):1346-1349

[16] 夏伟,马德营,王翎等. 高透腔面大功率650 nm 红光半导体激光器[J]. 中国激光,2007,34(9):1182-1184

Xia Wei,Ma Deying,Wang Ling et al.. High power 650 nm red semiconductor laser with transparent window[J]. Chinese J. Lasers,2007,34(9):1182-1184

[17] R. R. Wang,L. M. Yang,Y. H. Wang et al.. Sifuvirtide,a potent HIV fusion inhibitor peptide[J]. Biochem. Biophys. Res. Commun.,2009,382(3):540~544

[18] R. R. Wang,Q. Gu,Y. H. Wang et al.. Anti-HIV-1 activities of compounds isolated from the medicinal plant Rhus chinensis[J]. J. Ethnopharmacol.,2008,117(2):249-256

[19] M. Wainwright. Methylene blue derivatives suitable photoantimicrobials for blood product disinfection [J]. Int. J. Antimicrob. Agents.,2000,16(4):381-394

[20] S. Kiertiburanakul,S. Sungkanuparph. Emerging of HIV drug resistance:epidemiology,diagnosis,treatment and prevention[J]. Curr. HIV Res.,2009,7(3):273-278

[21] S. K. Chiao,D. L. Romero,D. E. Johnson. Current HIV therapeutics:mechanistic and chemical determinants of toxicity [J]. Curr. Opin. Drug. Discov. Devel.,2009,12(1):53-60

[22] B. G. Solheim,J. Seghatchian. Update on pathogen reduction technology for therapeutic plasma:an overview [J]. Transfus. Apher. Sci.,2006,35(1):83-90

[23] B. Horowits,S. Rywkin,H. Margolis-Nunno et al.. Inactivation of viruses in red cell and platelet concentrates with aluminum phthalocyanine (AIPc) sulfonates [J]. Blood Cells.,1992,18(1):141-149

[24] D. S. Dimitrov,R. Blumenthal. Photoinactivation and kinetics of membrane fusion mediated by the human immunodeficiency virus type 1 envelope glycoprotein [J]. J. Virol.,1994,68(3):1956-1961

[25] C. Vever-Bizet,A. S. Boutorine,O. Delgado et al.. Targeting of HIV gp120 by oligonucleotide-photosensitizer conjugates. light-induced damages [J]. FEBS Lett.,1999,462(3):467-471

[26] 于丽,李晓原. 第二代光敏剂血卟啉单甲醚及其临床应用研究进展[J]. 生物医学工程与临床,2005,9(6):365-368

Yu Li,Li Xiaoyuan. Advances in the second generation of photosensitizer hematoporphyrin monomenthyl ether and its clinical applications [J]. BME & Clin. Med.,2005,9(6):365-368

[27] Huijuan Yin,Yingxin Li,Zhaohui Zou et al.. Inactivation of bovine immunodeficiency virus by photodynamic therapy with HMME[J]. Chin. Opt. Lett.,2008,6(12):944-946

阴慧娟, 郑永唐, 李迎新, 李春艳, 邹朝辉, 赵宇. 光动力疗法抑制人免疫缺陷病毒复制的实验研究[J]. 中国激光, 2009, 36(10): 2705. Yin Huijuan, Zheng Yongtang, Li Yingxin, Li Chunyan, Zou Zhaohui, Zhao Yu. Photochemical Inactivation of Cell-Associated and Cell-Free Human Immunodeficiency Virus in Vitro[J]. Chinese Journal of Lasers, 2009, 36(10): 2705.

光动力疗法抑制人免疫缺陷病毒复制的实验研究

关于本站 Cookie 的使用提示

全站搜索

光动力疗法抑制人免疫缺陷病毒复制的实验研究

相关论文

相关资讯

关于本站 Cookie 的使用提示

全站搜索